Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

PIPELINE

PRE-CLINICAL

CLINICAL

Partner

CAR-T (Off-the-Shelf)

T-ALL/LBL

WU-CART-007

Memory NK (1:1)

AML

WU-NK-101

AML

WU-NK-101 Asia (China, HK, Macao, Taiwan & Singapore)

Memory NK (Off-the-Shelf)

AML

WU-NK-101

Solid Tumors

WU-NK-101 + mAb

Solid Tumors

WU-NK-201 Engineered

LATEST NEWS

Wugen to Present at the Upcoming Jefferies Cell & Genetic Medicine Summit

SAINT LOUIS, MO and SAN DIEGO, CA, September 23, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…

Read more
Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic…

Read more
Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors

Cell therapy veteran Natalie Mount, Ph.D., brings more than 25 years of industry experience ST. LOUIS, MO and SAN DIEGO,…

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis